Lineage Cell Therapeutics Inc Cash Flow Reinvestment Rate

Latest as of March 2022: 0.00x

Lineage Cell Therapeutics Inc cash flow reinvestment rate. Lineage Cell Therapeutics Inc (LCTX) has a Cash Flow Reinvestment Rate of 0.00x as of March 2022, reinvesting $92.00K (capex $46.00K plus investments $-46.00K) from operating cash flow of $21.90 Million. Explore Lineage Cell Therapeutics Inc cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.

Reinvestment Rate

0.00x

(Capex + Investments) / Operating CF

Total Reinvested

$92.00K

Capex + Investments

Operating Cash Flow

$21.90 Million

USD

Capital Expenditures

$46.00K

USD

Cash Flow Reinvestment Rate of Lineage Cell Therapeutics Inc (2022–2022)

Cash flow reinvestment rate of Lineage Cell Therapeutics Inc from 2022 to 2022. Historical reinvestment intensity for Lineage Cell Therapeutics Inc across 1 annual periods. Explore Lineage Cell Therapeutics Inc capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.

Lineage Cell Therapeutics Inc Cash Flow Reinvestment Rate by Year (2022–2022)

Lineage Cell Therapeutics Inc cash flow reinvestment rate by year from 2022 to 2022. Year-by-year capital reinvestment analysis for Lineage Cell Therapeutics Inc. For the full cash flow conversion analysis, see Lineage Cell Therapeutics Inc operating cash flow efficiency.

Year	Reinvestment Rate	Total Reinvested (USD)	Operating CF	Capex	YoY Change
2022	43.59x	$46.16 Million	$1.06 Million	$413.00K	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow